- Home
- CGEM vs BFST Comparison
CGEM vs BFST Comparison
Compare CGEM & BFST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CGEM | BFST |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.0B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CGEM | BFST |
|---|---|---|
| Price | $21.82 | $31.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $30.13 | ★ $32.75 |
| AVG Volume (30 Days) | ★ 670.9K | 210.8K |
| Earning Date | 05-11-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 2.23% |
| EPS Growth | N/A | ★ 23.45 |
| EPS | N/A | ★ 1.37 |
| Revenue | N/A | ★ $10,704,000.00 |
| Revenue This Year | N/A | $22.71 |
| Revenue Next Year | $5.20 | $5.02 |
| P/E Ratio | ★ N/A | $22.74 |
| Revenue Growth | N/A | ★ 1.20 |
| 52 Week Low | $5.68 | $22.56 |
| 52 Week High | $22.54 | $32.53 |
Technical Indicators
Market Signals| Indicator | CGEM | BFST |
|---|---|---|
| Relative Strength Index (RSI) | 69.64 | 48.71 |
| Support Level | $16.40 | $31.26 |
| Resistance Level | N/A | $31.49 |
| Average True Range (ATR) | 1.21 | 0.51 |
| MACD | 0.30 | -0.17 |
| Stochastic Oscillator | 88.78 | 30.77 |
Price Performance
Historical ComparisonAbout CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
About BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.